UCLB spinout, Autolus, features in a recent Fierce Biotech article, after filing to raise $100 million in a Nasdaq IPO.
The clinical stage biopharmaceutical company was founded upon the work of Dr Martin Pule, a UCL academic, clinical haematologist and thought leader in T-cell engineering. So far it has secured over $170 million through venture funding, to aid in its development of next-generation, programmed T cell therapies for the treatment of cancer.
In its article Fierce Biotech outlines how Autolus, who recently announced a license agreement with UCLB, would utilise further capital raised through an IPO.
To read more about this story click here: